140 related articles for article (PubMed ID: 15967729)
1. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach.
Kiang AS; Palfi A; Ader M; Kenna PF; Millington-Ward S; Clark G; Kennan A; O'reilly M; Tam LC; Aherne A; McNally N; Humphries P; Farrar GJ
Mol Ther; 2005 Sep; 12(3):555-61. PubMed ID: 15967729
[TBL] [Abstract][Full Text] [Related]
2. RNAi-based suppression and replacement of rds-peripherin in retinal organotypic culture.
Palfi A; Ader M; Kiang AS; Millington-Ward S; Clark G; O'Reilly M; McMahon HP; Kenna PF; Humphries P; Farrar GJ
Hum Mutat; 2006 Mar; 27(3):260-8. PubMed ID: 16419083
[TBL] [Abstract][Full Text] [Related]
3. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference.
Cashman SM; Binkley EA; Kumar-Singh R
Gene Ther; 2005 Aug; 12(15):1223-8. PubMed ID: 15877050
[TBL] [Abstract][Full Text] [Related]
4. A transgenic mouse model for gene therapy of rhodopsin-linked Retinitis Pigmentosa.
O'Reilly M; Millington-Ward S; Palfi A; Chadderton N; Cronin T; McNally N; Humphries MM; Humphries P; Kenna PF; Farrar GJ
Vision Res; 2008 Feb; 48(3):386-91. PubMed ID: 17920651
[TBL] [Abstract][Full Text] [Related]
5. Cellular expression and siRNA-mediated interference of rhodopsin cis-acting splicing mutants associated with autosomal dominant retinitis pigmentosa.
Hernan I; Gamundi MJ; Planas E; Borràs E; Maseras M; Carballo M
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3723-9. PubMed ID: 21357407
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).
Tam LC; Kiang AS; Kennan A; Kenna PF; Chadderton N; Ader M; Palfi A; Aherne A; Ayuso C; Campbell M; Reynolds A; McKee A; Humphries MM; Farrar GJ; Humphries P
Hum Mol Genet; 2008 Jul; 17(14):2084-100. PubMed ID: 18385099
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach.
Gorbatyuk MS; Pang JJ; Thomas J; Hauswirth WW; Lewin AS
Mol Vis; 2005 Aug; 11():648-56. PubMed ID: 16145542
[TBL] [Abstract][Full Text] [Related]
8. Choice of the adequate detection time for the accurate evaluation of the efficiency of siRNA-induced gene silencing.
Choi I; Cho BR; Kim D; Miyagawa S; Kubo T; Kim JY; Park CG; Hwang WS; Lee JS; Ahn C
J Biotechnol; 2005 Nov; 120(3):251-61. PubMed ID: 16095743
[TBL] [Abstract][Full Text] [Related]
9. Gene-based therapies for dominantly inherited retinopathies.
Farrar GJ; Millington-Ward S; Chadderton N; Humphries P; Kenna PF
Gene Ther; 2012 Feb; 19(2):137-44. PubMed ID: 22089493
[TBL] [Abstract][Full Text] [Related]
10. Retinopathy mutations in the bZIP protein NRL alter phosphorylation and transcriptional activity.
Kanda A; Friedman JS; Nishiguchi KM; Swaroop A
Hum Mutat; 2007 Jun; 28(6):589-98. PubMed ID: 17335001
[TBL] [Abstract][Full Text] [Related]
11. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa.
O'Neill B; Millington-Ward S; O'Reilly M; Tuohy G; Kiang AS; Kenna PF; Humphries P; Farrar GJ
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2863-9. PubMed ID: 10967039
[TBL] [Abstract][Full Text] [Related]
12. [Triple helix: a new promise for gene therapy].
Intödy Z; Perkins BD; Wilson JH
Orv Hetil; 2003 Apr; 144(16):757-63. PubMed ID: 12778626
[TBL] [Abstract][Full Text] [Related]
13. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
[TBL] [Abstract][Full Text] [Related]
14. An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.
Shaw LC; Skold A; Wong F; Petters R; Hauswirth WW; Lewin AS
Mol Vis; 2001 Jan; 7():6-13. PubMed ID: 11172137
[TBL] [Abstract][Full Text] [Related]
15. Aberrant retinal tight junction and adherens junction protein expression in an animal model of autosomal dominant Retinitis pigmentosa: the Rho(-/-) mouse.
Campbell M; Humphries M; Kennan A; Kenna P; Humphries P; Brankin B
Exp Eye Res; 2006 Sep; 83(3):484-92. PubMed ID: 16643895
[TBL] [Abstract][Full Text] [Related]
16. RNAi of COL1A1 in mesenchymal progenitor cells.
Millington-Ward S; McMahon HP; Allen D; Tuohy G; Kiang AS; Palfi A; Kenna PF; Humphries P; Farrar GJ
Eur J Hum Genet; 2004 Oct; 12(10):864-6. PubMed ID: 15241481
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
Tao J; Tu YT; Huang CZ; Feng AP; Wu Q; Lian YJ; Zhang LX; Zhang XP; Shen GX
Br J Dermatol; 2005 Oct; 153(4):715-24. PubMed ID: 16181451
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa.
Gamundi MJ; Hernan I; Muntanyola M; Maseras M; López-Romero P; Alvarez R; Dopazo A; Borrego S; Carballo M
Hum Mutat; 2008 Jun; 29(6):869-78. PubMed ID: 18412284
[TBL] [Abstract][Full Text] [Related]
20. PRPF31 alternative splicing and expression in human retina.
Tanackovic G; Rivolta C
Ophthalmic Genet; 2009 Jun; 30(2):76-83. PubMed ID: 19373678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
